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Objectives. Stent implantation reduces restenosis in vessels
>23 mm compared with balloon angioplasty, but few data are
available for stents implanted in vessels <3 mm. The aim of this
study was to evaluate immediate and follow-up patient outcomes
after stent implantation in vessels <3 mm compared to stent
implantation in vessels >23 mm.
Methods. Between March 1993 and May 1996, a total of 1,298
consecutive patients (1,673 lesions) underwent coronary stenting.
The study population was divided into two groups based on
angiographic vessel diameter. In case of multivessel stenting,
patients were randomly assigned only one lesion. Group I in-
cluded 696 patients (696 lesions) in whom stents were implanted
in vessels >23 mm, and group II included 602 patients (602
lesions) in whom stents were implanted in vessels <3 mm.
Results. There was no difference in procedural success (95.4%
in group I and 95.9% in group II), or subsequent subacute stent
thrombosis (1.5% in group I and 1.4% in group II, p 5 NS). The
postprocedure residual diameter stenosis was 3.31 6 12.4% in
group I and 22.45 6 16.2% in group II. Angiographic follow-up
was performed in 75% of patients, restenosis occurred in 19.9% of
patients in group I and 32.6% in group II (p <0.0001). Absolute
lumen gain was significantly higher in group I compared to group
II, but absolute late lumen loss was similar in the two groups
(1.05 6 0.91 mm in group I vs. 1.11 6 0.85 mm in group II, p 5
NS). Subsequently, the loss index was more favorable in group I
(0.45 vs. 0.56; p 5 0.0006). Independent predictors of freedom
from restenosis by multivariate logistic regression in the total
population were: larger baseline reference diameter (odds ratio
2.032 p 5 0.006), larger postprocedure minimal stent cross-
sectional area (odds ratio 1.190, p 5 0.0001) and shorter lesions
(odds ratio 1.037, p 5 0.01). At long-term clinical follow-up,
patients with small vessels had a lower rate of event-free survival
(63% vs. 71.3%, p 5 0.007).
Conclusions. Coronary stenting can be performed in small
vessels with a high success rate and low incidence of stent
thrombosis. However, the long-term angiographic and clinical
outcome of patients undergoing stent implantation in small
vessels is less favorable than that of patients with large vessels.
(J Am Coll Cardiol 1998;32:1610–8)
©1998 by the American College of Cardiology
Coronary stents have reduced restenosis in focal lesions in
vessels with an angiographic reference diameter equal or
greater than 3.0 mm compared to balloon angioplasty (1–3).
Recently, the benefits of stenting in small vessels, compared to
balloon angioplasty, were reported (4). Improvements in stent
implantation technique and postprocedural pharmacological
treatment reduced stent thrombosis and bleeding complica-
tions (5–7), leading to the use of coronary stenting in more
complex lesion subsets (8) including lesions in small vessels.
Initial reports have suggested a higher incidence of subacute
thrombosis and restenosis when stents are implanted in small
vessels.
The purpose of this study was to assess the immediate and
long-term outcomes of patients undergoing stenting in small
vessels and to compare those to the outcomes of patients
undergoing stenting in larger vessels using similar technique
and postprocedure pharmacological therapy.
Methods
Patient population. Between March 30, 1993, and May 31,
1996, a total of 1,298 consecutive patients (1,673 lesions)
underwent coronary stenting at Columbus Hospital in Milan,
Italy. All patients had a significant angiographic stenosis
($50% diameter stenosis) associated with clinical or objective
evidence of myocardial ischemia. Patients were divided into
two groups based on the angiographic proximal reference
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diameter before intervention (in case of multivessel stenting,
patients were randomly assigned only one lesion): group I
included 696 patients (696 lesions) with reference diameter
$3 mm, and group II included 602 patients (602 lesions) with
reference diameter ,3 mm.
Quantitative angiographic measurements. Patients re-
ceived intracoronary isosorbide-dinitrate (2–5 mg) prior to
initial postprocedure and follow-up angiograms to achieve
maximal vasodilation. The guiding catheter was used for
calibration. Measurements were made from an optically mag-
nified image in a single matched “worst” view. Digital calipers
(Brown and Sharp, North Kingstown, RI) were used until July
1995 (870 lesions; 67%); subsequently, a computerized quan-
titative analysis system (QCA-CMS system version 3.0,
MEDIS, Leiden, The Netherlands) was used. Previous studies
have shown that digital calipers correlate closely with
computer-assisted methods with a low interobserver and in-
traobserver variability (9).
In our laboratory, interobserver reproducibility was as-
sessed by two experienced angiographers who performed
blinded measurements of randomly selected coronary seg-
ments (n 5 20). Intraobserver reproducibility was based on
blinded measurements performed at a different time. Intraob-
server correlation coefficient (r) was 0.98 (p , 0.0001, 95% CI
[confidence interval] 0.96 to 0.99) for reference measurements
and 0.91 (p , 0.0001, 95% CI, 0.71 to 0.97) for intrastent
minimal lumen diameter. Interobserver correlation coefficient
was 0.95 (p , 0.0001, 95% CI, 0.87 to 0.98) for reference
measurements and 0.90 (p , 0.0001, 95% CI, 0.68 to 0.97) for
intrastent minimal lumen diameter.
Angiographic measurements included proximal and distal
reference diameter, minimum lumen diameter (MLD), per-
cent diameter stenosis and lesion length. Lesion length was
measured on the baseline angiogram as the distance from the
proximal to distal lesion shoulder. Relative gain, relative loss
and net gain indexes were also calculated (10). Relative gain
represents the improvement in MLD as a result of the inter-
vention normalized for vessel size and is calculated as (post-
procedure MLD minus preprocedure MLD) divided by prein-
tervention reference diameter. Relative loss is the change in
MLD from postprocedure to the follow-up angiogram normal-
ized for vessel size and is calculated as (post-procedure MLD
minus MLD at follow-up) divided by preintervention reference
diameter. Loss index reflects the percentage of acute gain that
is lost at follow-up and is calculated as (postprocedure MLD
minus MLD at follow-up) divided by acute gain. Lesions were
characterized according to the modified AHA/ACC (American
Heart Association/American College of Cardiology) classifica-
tion (11).
Intravascular ultrasound equipment and measurements.
A mechanical 3.2F ultrasound catheter (CVIS, Boston Scien-
tific, Sunnyvale, CA) was used. Validation of quantitative
measurements and pathologic correlation with ultrasound
measurements have both been reported (12,13). Images were
initially obtained using a manual pullback. After July 1994, a
mechanical pullback system at a constant speed of 0.5 mm/s
was used. The position of the catheter on fluoroscopy was used
to correlate the ultrasound image with the angiogram and a
voice comment was recorded during pullback. The ultrasound
runs were stored on 0.5-inch super VHS videotape and imme-
diate quantitative analysis was performed after each pullback.
Lumen and vessel cross-sectional areas (CSAs) were mea-
sured with the use of a trackball to outline the lumen-intima
interface and the media-adventitia interface, respectively. The
smallest lumen area within the stent was selected for measure-
ment in each passage of the intravascular ultrasound (IVUS)
catheter. Reference lumen CSAs were measured proximal and
distal to the stented segment in the closest and most normal
appearing segments. The average reference vessel and lumen
CSAs were calculated as the average of the proximal and distal
reference vessel and lumen CSAs. Interobserver and intraob-
server reproducibility of MLD and lumen CSA measurements
have already been reported (14).
Stent implantation procedure. Intracoronary stenting was
performed using techniques previously described (15–17). Pa-
tients received aspirin 325 mg and continued their standard
antianginal therapy before the stent procedure. A bolus of
10,000 U of heparin was administered after insertion of the
femoral sheath. If necessary, a repeat bolus of heparin 2,500 U
was given to maintain the activated clotting time (ACT)
greater than 250 s. Patients did not receive dextran or dipyr-
idamole before, during or following the stent procedure.
Different stents types were used; the Palmaz-Schatz stent
(Johnson and Johnson Interventional Systems, Warren, NJ)
was the most frequently used stent (795 lesions; 61.2%). Other
stents implanted were the Gianturco-Roubin I stent (Cook
Cardiology, Bloomington, IN) (105 lesions; 8.1%); the NIR
stent (SciMed, Boston Scientific, Maple Grove, MN) (73
lesions; 5.6%); the Wiktor stent (Medtronic, San Diego, CA)
(69 lesions; 5.3%); the Wallstent (Schneider Europe, Bulach,
Switzerland) (43 lesions; 3.3%); the AVE Micro stent II
(Applied Vascular Engineering, Santa Clara, CA) (42 lesions;
3.2%); the tantalum Cordis stent (Cordis Corp., Miami, FL)
(25 lesions; 1.9%); the BeStent (Medtronic, Minneapolis, MN)
(18 lesions; 1.4%); the Crown stent (Johnson and Johnson
Interventional Systems, Warren, NJ) (7 lesions; 0.5%); the
ACS Multilink stent (Guidant, Temecula, CA) (7 lesions;
0.5%); the Angiostent (AngioDynamics, Glens Falls, NY) (4
Abbreviations and Acronyms
ACT 5 activated clotting time
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CSA 5 cross-sectional area
ECG 5 electrocardiogram
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PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 thrombolysis in myocardial infarction
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lesions; 0.3%); the ACT I stent (Progressive Angiography
Systems, Menlo Park, CA) (2 lesions; 0.2%), or a combination
of different stents (103 lesions; 7.9%). The decision to choose
a particular stent type (slotted tube or coil stent) was based on
several factors, among which were lesion location (aorto-ostial,
side-branch at the lesion site, location at a bend, location distal
to a tortuous segment), presence of calcifications and occa-
sionally on the availability of appropriate stent lengths.
After stent implantation, angiographic optimization was
performed to achieve a good angiographic result with ,20%
residual stenosis by visual estimate. Intravascular ultrasound
was performed in the majority of cases after optimization of
the angiographic result. The IVUS success was defined as the
achievement of a final minimum intrastent CSA $60% of the
average proximal and distal reference vessel CSA or a final
minimum intrastent CSA larger than the distal reference
lumen CSA. However, the use of IVUS interrogation after
stenting during the period of this study was not based on
random assignment but on operator decision; therefore, some
patients did not undergo IVUS interrogation. Indications for
stenting were defined as previously described (17).
Postprocedure pharmacological therapy. A total of 1,241
patients (96%) were treated only with antiplatelet medications,
ticlopidine and aspirin in 950 patients (77%) and aspirin alone
in 291 patients (23%). Before March 1995, a total of 57
patients (5%) were treated with a standard anticoagulation
regimen consisting of warfarin for 2 months and aspirin
indefinitely. This group included 17 patients with thrombus
and slow flow after the procedure, 17 patients with suboptimal
final IVUS results, 3 patients with inadequate lesion coverage
because of the inability to deliver a stent; the remaining
patients were on warfarin for other indications.
Definitions. Study end points were: 1) angiographic resten-
osis defined as the presence of $50% diameter stenosis at the
treated site at follow-up angiography; and 2) event-free sur-
vival defined as survival in the absence of CABG, myocardial
infarction (MI) (Q wave or non-Q wave), and repeat interven-
tion. Death was defined as any death irrespective of the cause.
A diagnosis of Q-wave MI was made when there was docu-
mentation of new pathological Q waves (.0.04 s) on an
electrocardiogram (ECG) in conjunction with elevation in
creatine kinase to greater than twice the upper limit of normal.
A diagnosis of non-Q-wave MI was made when an elevation of
the cardiac enzymes to greater than twice the upper limit of
normal was documented without the development of new
pathological Q waves. Emergency CABG was defined as any
CABG performed during the hospitalization of the patient.
Acute thrombosis events were angiographic-documented stent
thrombosis occurring within 24 h of the procedure. Subacute
thrombosis events were angiographically documented occlu-
sions with TIMI flow grade 0 or 1 at the stent site occurring
beyond 24 h to 2 months after the stent procedure, or sudden
death occurring within 2 months after the procedure.
Statistical analysis. Data were analyzed with the SAS
statistical system software version 6.11. Categorical variables
are presented as absolute numbers and percentages. Continu-
ous variables are presented as mean 6 SD. Subgroup compar-
isons were performed by chi-square analysis for categorical
variables and by the Student t test for continuous variables.
The role of clinical, angiographic and procedural variables in
influencing restenosis was evaluated with multivariate logistic
regression analysis. First, univariate analysis was performed,
then variables that were found to be significant were entered
into a stepwised logistic regression model to determine the
independent predictors of freedom from restenosis. Probabil-
ity values ,0.05 were considered significant. Kaplan-Meier
survival analysis and the log-rank test were used to evaluate the
composite end point of death, MI, CABG or target lesion
revascularization during the first 12 months after stenting.
Results
Patient and lesion characteristics. The clinical character-
istics of the two groups are shown in Table 1. There were no
differences in clinical risk factors, ejection fraction, unstable
angina and frequency of multivessel disease. As shown in Table
2, there was no difference in lesion type (AHA/ACC), presence
of total occlusions, calcification and bifurcations.
Patients who returned for follow-up angiography had sim-
ilar baseline clinical and angiographic characteristics com-
pared to those who did not return for follow-up (Table 3).
Procedural, quantitative angiographic and IVUS analysis.
As shown in Table 4, baseline angiographic reference diameter
was 3.43 6 0.39 mm in group I vs. 2.63 6 0.29 mm in group II
(p , 0.0001), but there was no difference in lesion length or
severity. The balloon-to-artery ratio used for final stent expan-
sion was significantly higher in group II compared to group I
(1.29 6 0.20 vs. 1.09 6 0.14, p , 0.0001), but there was no
difference in number of stents per lesion or final pressure used
for stent expansion.
The IVUS guidance was used in similar frequency in both
Table 1. Patients’ Clinical Characteristics
Group I (696 pts)
(Large vessels)
Group II (602 pts)
(Small vessels)
p
Value
Male (%) 83.5% 82.5% NS
Age (years) 59.0 6 9.4 58.8 6 9.7 NS
Hyperlipidemia (%) 376 (54.0%) 317 (52.7%) NS
Family history (%) 278 (39.9%) 264 (43.8%) NS
Hypertension (%) 284 (40.8%) 241 (40.0%) NS
Diabetes (%) 79 (11.4%) 76 (12.6%) NS
Smoking (%) 429 (61.6%) 370 (61.5%) NS
Previous MI (%) 378 (54.3%) 316 (52.5%) NS
Previous PTCA (%) 80 (11.5%) 80 (13.2%) NS
Previous CABG (%) 75 (10.8%) 60 (10.0%) NS
Multivessel disease (%) 361 (51.9%) 349 (57.9%) NS
Unstable angina (%) 246 (35.3%) 175 (29.1%) NS
Ejection fraction (%) 57.3 6 11.2 57.2 6 10.1 NS
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groups. The average reference vessel diameter (media to
media) by IVUS was 3.78 6 0.51 mm in small vessels and
4.35 6 0.58 mm in large vessels (p 5 0.001). Accordingly, if the
balloon-to-vessel ratio (B/V) was calculated using IVUS vessel
size, the B/V ratio would be 0.91 6 0.12 in small vessels and
0.88 6 0.10 in large vessels (p 5 0.006).
Procedural outcome and short-term events. High rate of
procedural success was achieved in both groups (95.4% in
group I and 95.9% in group II). As shown in Table 5, there was
no difference in incidence of procedural complications and in
incidence of acute and subacute stent thrombosis.
Incidence of angiographic restenosis. Angiographic
follow-up was obtained in 74% and 75% of patients at a mean
duration of 5.6 6 2.0 and 5.6 6 2.1 months in groups I and II,
respectively (p 5 NS). As shown in Table 6, there was no
difference in stent type distribution between the two groups.
The quantitative angiographic measurements for lesions that
had angiographic follow-up are shown in Table 7. A signifi-
cantly larger absolute lumen gain was achieved in group I
compared to group II (2.42 mm vs. 2.06 mm; p , 0.0001), but
the absolute late lumen loss was similar between both groups
(1.05 6 0.91 mm vs. 1.11 6 0.85 mm, p 5 NS). This resulted in
a more favorable loss index (0.45 vs. 0.56; p 5 0.0006) in group
I, as shown in Figure 1. Subsequently, the binary restenosis rate
was 19.9% in group I vs. 32.6% in group II (p , 0.0001). The
incidence of angiographic restenosis varied according to stent
design (slotted tubular vs. coil stents) (Fig. 2). For slotted
tubular stents, restenosis remained significantly lower in large
vessels compared to small vessels (16.7% vs. 27.7%; p 5
0.0012). However, there was no statistical difference in resten-
osis between large and small vessels when coil stents were
implanted (32.1% vs. 32.6%; p 5 NS).
Also, the incidence of restenosis varied according to the use
of IVUS guidance. Restenosis rates were lower when IVUS
guidance was used in patients with large vessels and in patients
with small vessels, as shown in Table 7. However, the reduction
in restenosis was primarily due to achieving an optimal IVUS
result. In the large vessel group, restenosis was 15% when an
optimal IVUS result was achieved (249 lesions) compared to
24% when an optimal IVUS result was not achieved (101
lesions), p 5 0.036. Similarly, in the small vessel group,
restenosis was 26% when an optimal IVUS result was achieved
(223 lesions) compared to 37% when an optimal IVUS result
was not achieved (89 lesions), p 5 0.043.
Predictors of freedom from angiographic restenosis. Table
8 shows a comparison between restenotic and nonrestenotic
lesions in all patients who underwent IVUS guided stenting.
All clinical, lesion and procedural characteristics that were
found to be significantly different between the two groups were
entered into a stepwise multivariate logistic regression model,
as shown in Table 9. Factors that independently predicted a
Table 2. Angiographic Lesion Characteristics
Group I
(n 5 696)
(Large vessels)
Group II
(n 5 602)
(Small vessels)
p
Value
Vessel distribution 0.001
Left main 12 (1.7%) 2 (0.3%)
LAD 315 (45.2%) 360 (59.8%)
RCA 234 (33.6%) 104 (17.3%)
LCx 119 (16.6%) 137 (19.4%)
Vein graft 15 (2.2%) 15 (2.5%)
Lesion location 0.001
Ostium 45 (6.5%) 27 (4.5%)
Proximal 329 (47.3%) 233 (38.7%)
Mid 280 (40.2%) 288 (47.8%)
Distal 42 (6.0%) 54 (9.0%)
Type of lesion* NS
A 47 (6.8%) 31 (5.1%)
B1 229 (32.9%) 187 (31.1%)
B2 277 (39.8%) 246 (40.9%)
C 143 (20.5%) 138 (22.9%)
Total occlusion 77 (11.0%) 52 (9.6%) NS
Bifurcations 125 (18.0%) 124 (20.6%) NS
Angiographic
Calcium 106 (15.2%) 70 (11.6%) NS
Eccentricity 527 (75.7%) 450 (74.7%) NS
Irregularity 193 (27.8%) 194 (32.2%) NS
*According to ACC-AHA classification.
Table 3. Comparison Between Patients Who Had Follow-up
Angiography (Fu1) and Patients Who Did Not Have Follow-up
Angiography (Fu2) in the Total Study Population
Fu1
(n 5 966)
Fu2
(n 5 332)
p
Value
Clinical factors
Male (%) 88 86 0.44
Age (years) 57.9 6 9.3 58.7 6 10.1 0.15
Hyperlipidemia (%) 56 53 0.35
Hypertension (%) 40 43 0.28
Diabetes (%) 12 12 0.71
Smoking (%) 61 64 0.24
Unstable angina (%) 31 35 0.34
Ejection fraction (%) 58.1 6 10 58.1 6 10.7 0.73
Lesion characteristics 0.59
Left main 0.8 1.6
LAD 53 50
RCA 25 25
Lcx 18 20
Vein graft 2.3 2.3
Total occlusions 10 10 0.91
Bifurcations 19 20 0.61
Calcium 15 14 0.56
Procedural data
Balloon/Vessel ratio 1.18 6 0.19 1.17 6 0.21 0.26
Final maximum pressure (atm) 16.2 6 3.2 16.5 6 3.1 0.11
Stents/Lesion 1.6 6 1 1.5 6 1.2 0.37
Angiographic data
Reference diameter (mm) 3.06 6 0.53 3.07 6 0.52 0.72
Baseline MLD (mm) 0.87 6 0.47 0.85 6 0.48 0.44
Baseline diameter stenosis (%) 71.4 6 14.8 72.2 6 14.3 0.32
Lesion length (mm) 11 6 7 10.4 6 7.4 0.15
Final MLD (mm) 3.25 6 0.56 3.22 6 0.58 0.40
Final diameter stenosis (%) 22.9 6 13.1 22.5 6 14.1 0.64
Acute gain (mm) 2.25 6 0.66 2.20 6 0.65 0.24
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higher probability of freedom from restenosis were larger
baseline reference diameter (95% CI, 1.24 to 3.21, odds ratio
1.996, p 5 0.004), larger final intrastent CSA (95% CI, 1.09 to
1.34, odds ratio 1.205, p 5 0.0004), and shorter lesions (95%
CI, 1.02 to 1.07, odds ratio 1.041, p 5 0.001).
Long-term clinical outcome. Event-free survival during the
first 12 months after stenting in each group is shown in Figure
3. Patients with small vessels had a significantly lower rate of
event-free survival (63%) compared to patients with large
vessels (71.3%), p 5 0.007.
Discussion
The major findings of this study are the following: 1)
patients who undergo stent implantation in small vessels have
short-term outcome (1 month) similar to patients who undergo
stenting in larger vessels; in particular, the incidence of stent
thrombosis in small vessels is not higher than that in larger
vessels; 2) these results were obtained using a significantly
higher angiographic balloon-to-artery ratio for final stent
dilatation in small vessels compared to larger vessels; this
strategy points to the tendency of the operator to oversize
balloons more so in small vessels than in large vessels to attain
the maximal lumen gain possible; 3) small vessel stenting is
associated with a higher restenosis rate compared to stenting
larger vessels; 4) the loss index in small vessels is higher than
that in larger vessels; 5) the achievement of a large final CSA
inside the stent is a major variable associated with a lower
restenosis rate both in large and small vessels; 6) slotted
tubular stents perform better in large vessels compared to coil
stents; and 7) both stents perform suboptimally in preventing
restenosis rate when implanted in small vessels.
Previous studies using coil stents and oral anticoagulation
have suggested that stent thrombosis is higher when stents are
Table 4. Procedural Variables and Quantitative
Angiographic Measurements
Group I
(n 5 696)
(Large vessels)
Group II
(n 5 602)
(Small vessels)
p
Value
Angiographic data
Reference diameter 3.43 6 0.39 2.63 6 0.29 0.0001
Baseline MLD (mm) 0.94 6 0.53 0.78 6 0.38 0.0001
Baseline diameter stenosis (%) 71.6 6 14.9 70.6 6 14.2 NS
Lesion length (mm) 10.2 6 7.5 10.3 6 6.7 NS
Final MLD (mm) 3.31 6 0.53 2.86 6 0.47 0.0001
Final % stenosis (%) 3.31 6 12.4 22.45 6 16.2 0.0001
Procedural data
Final balloon size (mm) 3.72 6 0.50 3.34 6 0.40 0.0001
Balloon/Vessel ratio 1.09 6 0.14 1.29 6 0.20 0.0001
Final maximum pressure (atm) 16.4 6 3.1 16.0 6 3.2 NS
Stents/Lesion 1.5 6 0.9 1.5 6 1.1 NS
IVUS guided stenting 70% 69% NS
Table 5. Procedural and Short-Term Events
Group I
(Large vessels)
Group II
(Small vessels) p Value
Procedural MI (%)
non-Q wave MI 20 (2.9%) 22 (3.7%) NS
Q wave MI 8 (1.1%) 8 (1.3%) NS
Emergency CABG 12 (1.7%) 11 (1.8%) NS
Procedural death 2 (0.2%) 1 (0.2%) NS
Acute thrombosis 4 (0.6%) 3 (0.6%) NS
Subacute thrombosis 10 (1.4%) 9 (1.5%) NS
Table 6. Stent Type Distribution in Patients With
Follow-up Angiography
Number of lesions
Group I
(Large vessels)
(n 5 515)
Group II
(Small vessels)
(n 5 451)
Palmaz-Schatz (n 5 668) 370 (71.8%) 298 (66.1%)
Combination (n 5 102) 44 (8.5%) 58 (12.9%)
GR stent (n 5 54) 27 (5.2%) 27 (6.0%)
Wiktor (n 5 36) 19 (3.7%) 17 (3.8%)
Wallstent (n 5 28) 14 (2.7%) 14 (3.1%)
NIR (n 5 27) 14 (2.7%) 13 (2.9%)
AVE (n 5 15) 7 (1.4%) 8 (1.8%)
Cordis (n 5 10) 5 (1.0%) 5 (1.1%)
BeStent (n 5 10) 6 (1.2%) 4 (0.9%)
ACS (n 5 10) 6 (1.2%) 4 (0.9%)
Crown (n 5 4) 2 (0.4%) 2 (0.4%)
Angiostent (n 5 2) 1 (0.2%) 1 (0.2%)
Combination: combination of different types of stents.
Table 7. Quantitative Angiographic Measurements of Lesions With
Follow-up Angiography
Group I
(n 5 515)
(Large vessels)
Group II
(n 5 451)
(Small vessels)
p
Value
Baseline measurements
Reference diameter 3.45 6 0.39 2.64 6 0.28 0.0001
MLD (mm) 0.95 6 0.53 0.79 6 0.38 0.0001
Diameter stenosis (%) 71.0 6 14.9 70.0 6 14.5 NS
Lesion length (mm) 11.2 6 7.1 10.5 6 6.5 NS
Postprocedure measurements
MLD (mm) 3.37 6 0.54 2.85 6 0.44 0.0001
Diamter stenosis (%) 1.61 6 12.2 22.63 6 14.9 0.0001
Follow-up measurements
MLD (mm) 2.33 6 0.99 1.73 6 0.87 0.0001
Diameter stenosis (%) 28.2 6 27.9 37.5 6 29.8 0.0001
Acute gain 2.42 6 0.69 2.06 6 0.58 0.0001
Late loss 1.05 6 0.91 1.11 6 0.85 NS
Loss index 0.45 6 0.45 0.56 6 0.47 0.0006
Relative gain 0.71 6 0.19 0.79 6 0.23 0.0001
Relative loss 0.31 6 0.27 0.43 6 0.34 0.0001
Restenosis rate (%) 19.9% 32.6% 0.0001
Slotted tube stent 16.7% 27.7% 0.0012
Coil Stent 32.1% 32.6% NS
IVUS guidance 68% (n 5 350) 69% (n 5 312) 0.1335
Restenosis rate (%)
IVUS guide (1) 17% 29% 0.0001
IVUS guide (2) 26% 38% 0.0241
*p 5 0.0227; †p 5 0.0426.
]* ]†
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implanted in angiographically small vessels (18,19). However,
using the same regimen a recent subanalysis of the STRESS
trial (4) reported a stent thrombosis rate of 3.6% in vessels
,3 mm, which is similar to the stent thrombosis rate in the
total STRESS population (3.5%). In the present study, the
incidence of stent thrombosis was low in both large and small
vessels. The low incidence of stent thrombosis in small vessels
in this study is in agreement with other reports where aggres-
sive stent expansion was used with postprocedure antiplatelet
therapy (20,21). An exception is what was reported in the
French registry (6), where stent thrombosis occurred in 10% of
patients in whom final stent expansion was performed with
balloons ,2.5 mm despite using aspirin and ticlopidine ther-
apy. This may represent a subgroup of patients with small
vessels in whom undersized balloons were used for stent
expansion.
The combination of these observations highlights the im-
portance of appropriate stent expansion particularly in small
vessels. The use of IVUS guidance facilitates decision making
in terms of balloon sizing, especially in angiographically small
vessels that may in fact be large vessels with diffuse atheroscle-
rosis. Therefore, this fact has to be considered when angiog-
raphy alone is used for balloon sizing.
The incidence of restenosis was significantly higher follow-
ing the stenting of small vessels compared to stenting of larger
vessels. This finding is in agreement with previous studies after
standard percutaneous transluminal angioplasty (PTCA) and
atherectomy (22,23) but has not been consistently confirmed
following coronary stenting (24–29). In the present study, the
absolute lumen loss caused by intimal proliferation appears to
be similar in small and large vessels. The bigger postprocedural
lumen obtained in large vessels compared to smaller vessels is
the most possible explanation for the lower restenosis rate seen
following the stenting of large vessels. Serial IVUS studies
have shown that the main mechanism of restenosis after
nonstent coronary interventions is chronic vessel constriction
(30,31), whereas after stenting the restenotic process is entirely
due to intimal proliferation (32,33). It remains to be explained
why stenting elicits a relatively higher proliferative response in
small vessels. One possibility is that the process of lumen gain
in small vessels requires a higher degree of vessel wall stretch.
However, before discussing this issue, it should be pointed out
that it would be misleading to look only at the absolute values
of lumen gain and loss when evaluating patients with hetero-
geneous vessel sizes, the reason being that absolute lumen gain
is primarily dependent on vessel size, as shown in Figure 4.
This means that larger lumen gain could be obtained in large
vessels using a lower degree of vessel wall stretch compared to
what is needed in a smaller vessel. This concept could be better
Figure 1. Comparison of loss index in group I (large vessels) and
group II (small vessels).
Figure 2. Restenosis rates with different stent de-
signs in group I (large vessels) and group II (small
vessels).
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expressed using the “relative gain ratio,” which represents the
amount of lumen gain relative to vessel size. A higher relative
gain ratio, as found in the small vessel group, means a higher
proportional gain (stretch) applied to the vessel wall.
One may argue that, because the higher degree of vessel
trauma induced by an aggressive stent expansion strategy
(higher balloon-to-vessel ratio) is associated with higher loss
index, then perhaps a less aggressive strategy might be pre-
ferred. There are several observations that do not support such
an argument: 1) in this study, the balloon-to-artery ratio per se
was not predictive of restenosis in univariate or multivariate
analysis. Conversely, the final minimal CSA within the stent
was an independent predictor of freedom from restenosis in
the total population regardless of vessel size; and 2) a less
aggressive stent dilatation strategy in smaller vessels did not
result in lower restenosis in the STRESS trial (4). In that study,
the authors reported results of coronary stenting in vessels
,3 mm (mean vessel size 2.69 mm). Minimum lumen diameter
postprocedure and at follow-up was 2.26 mm and 1.54 mm,
respectively, compared to 2.85 mm and 1.73 mm in our study.
This resulted in a restenosis rate of 34% in the STRESS
subanalysis compared to 28% in patients who had slotted tube
stents in our study. This illustrates that a less aggressive
dilatation strategy does not decrease restenosis, but in fact may
increase it. Therefore, there is little advantage for a more
conventional limited stent expansion to limit vessel trauma in
small vessels. This strategy is likely to produce a final smaller
in-stent CSA with a negative net effect on the incidence of
stent thrombosis and restenosis.
Another possible explanation for the higher proliferative
response in small vessels is the higher metal density when a
stent designed to be implanted in large vessels is used in vessels
,3.0 mm. Stents specifically designed to achieve an optimal
radial force at a smaller diameter with a lower metal-to-vessel
surface ratio have been recently introduced and have a theo-
retical potential to improve the long-term results. An indirect
support to this concept comes from the observation that coil
stents had a similar effect on restenosis than slotted-tube stents
in small vessels, suggesting that the negative properties of
these stents (higher recoil and plaque prolapse) are counter-
balanced by the more favorable metal-to-vessel surface ratio.
In the present study, IVUS guidance was used in similar
frequency in both small and large vessels. Our findings suggest
that patients who had stent implantation under IVUS guid-
ance, in small or large vessels, had lower rate of restenosis
compared to patients where IVUS was not used. However, this
benefit was primarily present in patients where optimal stent
expansion was achieved. Unfortunately, in the small vessel
cohort an optimal IVUS result can be achieved in only 71% of
Figure 3. Kaplan-Meier survival curves for the combined end point of
death, myocardial infarction, coronary bypass surgery or target lesion
revascularization during the first 12 months after stenting in each
group.
Figure 4. Linear regression plot of acute lumen gain and baseline
angiographic reference diameter.
Table 8. A Comparison Between Patients With and Without
Restenosis in the Total Cohort With IVUS Guided Stenting
No Restenosis
(n 5 503)
Restenosis
(n 5 159)
p
Value
Clinical factors
Age (years) 57.1 6 9.2 58.6 6 9.9 0.09
Procedural factors
Balloon/Vessel ratio 1.18 6 0.17 1.21 6 0.20 0.25
Final pressure (atm) 16.0 6 3.2 16.3 6 3.1 0.26
Stents/Lesion 1.5 6 0.9 1.8 6 1.2 0.003
Quantitative angiographic
measurements
Reference diameter (mm) 3.14 6 0.52 2.89 6 0.45 0.001
Lesion length (mm) 10.6 6 6.7 12.4 6 7.7 0.008
Final MLD (mm) 3.25 6 0.56 2.96 6 0.48 0.001
Final % stenosis (%) 22.9 6 13.1 20.3 6 14.1 0.04
Acute gain 2.36 6 0.66 2.17 6 0.61 0.001
Quantitative IVUS
measurements
Average vessel CSA (mm2) 13.8 6 4.2 11.9 6 3.4 0.001
In-stent minimum LD (mm) 3.2 6 0.6 3.0 6 0.5 0.001
In-stent minimum CSA (mm2) 8.1 6 2.5 6.9 6 2.1 0.001
Optimal result in IVUS (%) 82% 64% 0.006
Table 9. Multivariate Predictors of Freedom From Restenosis in
Patients With IVUS-Guided Stenting in the Total Cohort: Stepwise
Multivariate Logistic Regression Analysis
Total cohort
Odds
Ratio CI
Standardized
Coefficient
p
Value
Angiographic reference
diameter
2.03 (1.22–3.38) 0.20 0.006
Final in-stent CSA 1.19 (1.07–1.33) 0.24 0.0001
Lesion length 1.04 (1.01–1.07) 20.14 0.01
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lesions. These data indicate that the use of IVUS per se does
not necessarily lead to reduction of restenosis unless the
information obtained is used appropriately to achieve the
maximal lumen gain safely possible. The fact that IVUS
guidance was used according to the intention of the operator
and not according to random assignment not only sets limita-
tions on this statement but also sets demands for a randomized
study to assess this issue better.
Study limitations. The most important limitation is that
this study was performed in a period of rapid technical
evolution. Subtle changes in decision making throughout the
study period are confounding factors that are difficult to detect.
The fact that this study is a retrospective single-center experi-
ence based on data that were acquired prospectively immedi-
ately after treatment and analyzed by investigators unaware of
the future clinical outcome gives uniformity and reliability to
these observations. However, this may also introduce an
element of uncertainty to the general application of the results
to settings where different techniques are used. In addition, the
use of IVUS guidance or slotted tube versus coil stents in this
study was based on operator decision and not random assign-
ment; therefore, the strength of conclusions made with respect
to the effect of these variables on incidence of restenosis is
limited. Despite these shortcomings, this study provides clini-
cally relevant information about the impact of vessel size on
long-term angiographic and clinical outcome of unselected
patients undergoing coronary stent implantation.
Conclusions. Coronary stenting can be safely applied in
small vessels; in particular, immediate success and incidence of
subacute thrombosis do not differ in relation to vessel size
provided appropriate antiplatelet therapy is given and an
optimal result is achieved. Despite these encouraging short-
term results, patients who undergo stent implantation in small
vessels have an angiographic restenosis rate higher than 30%
and a lower rate of event-free survival compared to patients
with larger vessels.
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